Your browser doesn't support javascript.
loading
Recomendaciones de uso de palivizumab para la prevención de la infección por virus respiratorio sincitial en prematuros de 321 a 350 semanas de gestación / Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (321 to 350 weeks of gestation)
Figueras Aloy, J; Carbonell Estrany, X.
Affiliation
  • Figueras Aloy, J; Hospital Clínic. Instituto de Ginecología, Obstetricia y Neonatología. Servicio de Neonatología. Barcelona. España
  • Carbonell Estrany, X; Hospital Clínic. Instituto de Ginecología, Obstetricia y Neonatología. Servicio de Neonatología. Barcelona. España
An. pediatr. (2003, Ed. impr.) ; 73(2): 98-98[e1-e4], ago. 2010.
Article in Spanish | IBECS | ID: ibc-82693
Responsible library: ES1.1
Localization: BNCS
RESUMEN
Los prematuros entre 321–350 semanas de gestación menores de 6 meses al inicio de la estación VRS o dados de alta durante la misma pueden beneficiarse de medidas higiénicas y de anticuerpos monoclonales para el virus respiratorio sincitial (Palivizumab) a fin de disminuir su hospitalización por esta infección. La Sociedad Española de Neonatología considera que, de acuerdo con la evidencia científica actual y en especial tras los resultados del estudio FLIP2 en población española, la profilaxis con palivizumab en prematuros de 321 a 350 semanas es muy recomendable cuando estén presentes los 2 factores de riesgo mayores (edad cronológica inferior a 10 semanas al comienzo de la estación o nacer en las 10 primeras semanas de la misma; tener al menos un hermano en edad escolar o de guardería o acudir a la misma). También se considera recomendable la profilaxis con palivizumab cuando estén presentes un factor mayor y 2 factores menores (antecedente de tabaquismo materno durante la gestación; sexo varón) (AU)
ABSTRACT
Late preterm infants (321 to 350 weeks gestation) aged less than 6 months at start of RSV station or discharged during this time may benefit from RSV monoclonal antibodies (palivizumab) administration to decrease the rates of RSV hospitalization. The Spanish Society of Neonatology considers, based on FLIP2 results in Spain, that palivizumab prophylaxis is strongly recommended if the “2 major risk factors” are present (chronological age less than 10 weeks at start of RSV season or being born during its first 10 weeks; sibling of school age or attending day-care assistance). Palivizumab is also recommended when “1 major risk factor and the 2 minor risk factors” are present. Minor risk factors are mother smoking during pregnancy and being a male (AU)
Subject(s)
Search on Google
Collection: National databases / Spain Health context: Sustainable Health Agenda for the Americas Health problem: Goal 9: Noncommunicable diseases and mental health / Goal 10: Communicable diseases Database: IBECS Main subject: Antibodies, Monoclonal Type of study: Etiology study / Practice guideline / Risk factors Limits: Child / Child, preschool / Female / Humans / Infant / Male Language: Spanish Journal: An. pediatr. (2003, Ed. impr.) Year: 2010 Document type: Article Institution/Affiliation country: Hospital Clínic/España
Search on Google
Collection: National databases / Spain Health context: Sustainable Health Agenda for the Americas Health problem: Goal 9: Noncommunicable diseases and mental health / Goal 10: Communicable diseases Database: IBECS Main subject: Antibodies, Monoclonal Type of study: Etiology study / Practice guideline / Risk factors Limits: Child / Child, preschool / Female / Humans / Infant / Male Language: Spanish Journal: An. pediatr. (2003, Ed. impr.) Year: 2010 Document type: Article Institution/Affiliation country: Hospital Clínic/España
...